New England Biolabs® and Mammoth Biosciences® Announce Global Licensing Agreement and Commercial Launch of MB-CasFire™ to Accelerate Isothermal Amplification-Based Assay Development
NEB will manufacture and globally distribute Mammoth Biosciences' proprietary CRISPR enzyme, equipping developers with a "one-pot" solution for highly-specific detection in LAMP, RPA and NEAR assays IPSWICH, Mass., Nov. 10, 2026 /PRNewswire/ -- New England Biolabs (NEB®) and Mammoth...
Covered in this story
Call it yourself
No calls on $NOV yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on NOV →Dalsna Finance is currently tracking 121 stories mentioning NOV, the earliest published 7 Oct 2025.
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.